Ligand Pharmaceuticals LGND AT220 — Financial Royalty Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's at220 — financial royalty assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's AT220 — financial royalty assets, net?
- Ligand Pharmaceuticals (LGND) reported AT220 — financial royalty assets, net of $4.66M in Q1 2026.
- What does AT220 — financial royalty assets, net mean?
- This metric represents the current carrying value of royalty assets for the AT220 segment after accounting for all applicable allowances and impairments. It provides the most accurate reflection of the asset's remaining economic value on the balance sheet, which is expected to generate future royalty income. Investors use this figure to assess the net book value of the company's investment in this specific product line and its potential for future earnings contribution.